Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TYR | P14679 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1028875 | 0.82 | TDP1 (0.44) | NPC1PKMRAB9AALDH1A1GAA | |
| SCHEMBL55828 | 0.81 | GAA (0.42) | NPC1ALDH1A1GAAMAPTGFER | |
| SCHEMBL3760045 | 0.79 | PTPN1 (0.46) | TP53TSHR | |
| SCHEMBL9725165 | 0.77 | SMN1; SMN2 (0.44) | NPC1RAB9AALDH1A1MAPTTP53 | |
| SCHEMBL11072074 | 0.75 | SMN1; SMN2 (0.33) | ALDH1A1TP53TSHRHSD17B10 | |
| SCHEMBL3128742 | 0.75 | ALDH1A1 (0.50) | ALDH1A1GAAMAPTTP53TYR | |
| SCHEMBL6033544 | 0.75 | SMN1; SMN2 (0.38) | NPC1RAB9AALDH1A1GAAMAPT | |
| SCHEMBL28043921 | 0.74 | — | — | |
| SCHEMBL97108 | 0.73 | HSD17B10 (0.48) | NPC1PKMRAB9AALDH1A1GAA | |
| SCHEMBL11465101 | 0.73 | SMN1; SMN2 (0.32) | MAPTTP53TSHRHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7300930-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-11-27 | — | — | US | disclosed |
| US-7205311-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED | 2007-04-17 | — | — | US | disclosed |
| US-7160896-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-01-09 | — | — | US | disclosed |
| US-20060111389-A1 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-05-25 | — | — | US | disclosed |
| US-20050070568-A1 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2005-03-31 | — | — | US | disclosed |
| EP-1474397-A1 | THERAPEUTIC ACRIDONE AND ACRIDINE COMPOUNDS | Cancer Research Technology Limited (GB) | 2004-11-10 | — | — | EP | disclosed |
| EP-1363888-A2 | THERAPEUTIC ACRIDONE AND ACRIDINE COMPOUNDS | Cancer Research Technology Limited (GB) | 2003-11-26 | — | — | EP | disclosed |
| US-20030207909-A1 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-11-06 | — | — | US | disclosed |
| WO-2003059885-A1 | THERAPEUTIC ACRIDONE AND ACRIDINE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-07-24 | — | — | WO | disclosed |
| WO-2002008193-A2 | THERAPEUTIC ACRIDONE AND ACRIDINE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207909-A1 | Therapeutic acridone and acridine compounds | NAT1, TERT, CCNA1 | NPC1 1038/4885PKM 3120/4885RAB9A 2984/4885 |
| US-20050070568-A1 | Therapeutic acridone and acridine compounds | CCNK, TERT, CCNA1 | NPC1 1422/4885PKM 2248/4885RAB9A 2371/4885 |
| US-20060111389-A1 | Therapeutic acridone and acridine compounds | TERT, ACIN1, NAT1 | NPC1 1419/4885PKM 3944/4885RAB9A 2492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.